Sign inJoin free

Watch / HealthTech

"The market’s 'weighty' overreaction..."

9 Nov 202312:08

"The market’s 'weighty' overreaction..."

General information only. ausbiz videos are general information only, produced by Ausbiz TV Pty Ltd, a media business that doesn’t give financial advice. They don’t take into account your objectives, financial situation or needs. Consider whether it’s right for you and read the PDS and TMD before acting on anything you watch.

About this video

Roger Montgomery, from Montgomery Investment Management, shares his views on investor sentiment surrounding the new generation GLP-1 medications. He cites the weight loss drug, Ozempic, as an example. In his view, while Ozempic will indeed increase the revenues of companies like Eli Lilly (NYSE: LLY) which received FDA approval recently, it may not be as transformative to the revenues of other companies negatively impacted by its advent such as CSL (CSL) and ResMed (RMD).

Roger draws a correlation between investor reactions and stock market fluctuations due to new developments in weight loss, with reference to McDonald's stock after the surge of low carb diets. He contends the fall and bounce-back in McDonald's stocks is a case study that demonstrates the fickleness of investors.

This could be reflected in the recent drop in CSL's share price due to market anxiety regarding competitive Ozempic-style drugs, which he feels might be unfounded.,He also warns against overreactions resulting from the introduction of drugs like Ozempic. According to Roger, obesity medications may not be as transformative in reducing the weight of the US population as investors anticipate.

Moreover, he suggests that not everyone who is obese will be able to afford such drugs, which can be expensive and require constant administration. His talk ends by propounding that innovative growth companies in the small cap space in Australia and the US could be the real defensive investment, owing to their potential rather than expensive defensives.

Find the full unedited transcript of this interview below:

And he says that the so-called Ozempic effect catalyzes a market reaction that warrants a closer look, suggesting the pendulum of investor sentiment may have swung too far towards pessimism for the companies thought to be negatively impacted by the advent of new generation GLP one's medications. Joining us now is Roger Montgomery from Montgomery Investment Management. Roger, thank you so much for joining the close. Always great to be on the show with you. And thanks for having me on. No problem at all. Gee, this has been the topic, almost the topic of the year, hasn't it? And indeed, it sure has. Yeah, and it's interesting because Eli Lilly just got FDA approval last night for yet another one of their weight loss drugs, which is very similar to the existing one, but their share prices have been on a tear, whereas poor old CSL and ResMed have been possibly overly penalized for a

0:59

narrative. So do tell us, Roger, what's your take?

1:03

Well, look, we know that the stock market is prone to bouts of elation and despondency. We know that they go through periods of, you know, people get really excited about something and then they get really depressed about the same thing. Often the ozempic effect does exactly what you described. And I think what it does is actually it's actually highlighting that tendency of investors to get too excited or too despondent about a particular, a particular event or development amongst companies. And, and the ozempic drug is is one of those things. So for example, before perhaps before we talk about his impact, let me just take us back 20 something years, 25 years or thereabouts at the turn of the century, um, when, you know, you might remember the Atkins low carb diet, you might have been on it yourself. Do you remember that? No, I wasn't on it. But I do remember there's been multiple phases of diets. My

2:03

gosh. Yeah, well, well, weight loss and exercise basically go hand in hand as partners on a merry go round of fads. And the Atkins was one of those. Now, between May 2002 and February 2003, McDonald's their stock fell 55%, mostly in reaction to the belief that the Atkins low carb diet was going to be transformative to the waistlines of people around the world, and the stock fell. I think it fell to $13.50. And McDonald's today trades at sort of circa $260. Um, and, and and the problem is for investors who get excited about these new developments in weight loss is that you've got very, very entrenched behaviors and very, very entrenched eating disorders that can't be fixed with a tablet that can't be fixed with a drug. Now, let me

3:02

clarify something. These drugs are going to be transformative to the revenues of the companies developing them, there's no doubt about that. And we'll talk about that if we get time in just a moment. But it's the negative reaction for all the other companies or some positive reactions for other companies that I think are probably misplaced. So, for example, we've seen airline stocks in the US

3:27

soar, pun intended. Um, and, and they've done that because people believe or investors believe that drugs like Ozempic are going to reduce the weight of the population of the United States to such an extent that airlines are going to have lower fuel costs and they're going to make more money. Yeah, it's a bit of a stretch, isn't it?

3:50

Another pun. Um,

3:52

it is. And, and and I think that's just taking things a little bit too far. So these GLP one medications including Ozempic, they will be transformational in terms of the revenue that they generate for companies like Novo Nordisk and Eli Lilly. No doubt about that. Um, those stocks might overreact as well on the upside. But I think in terms of revenues, they will make a big difference to those companies revenues. But with CSL, for example, its share price has dropped 25% from its February high. It's bounced a little bit off that today. And and you mentioned that in your introduction earlier in the program. That stock's up again 2% today. We bought a few weeks ago. We bought quite a bit of CSL, you know partly on this thesis. And because we know that it's a long term, long term fantastic business. The issue that you've got there is the sell off wiped $37 billion of Csl's market value. And yet what we know

4:52

is that the business that might be impacted, the vital kidney disease treatment business that that. That kidney disease, part of Viper is 40% of that division's revenue, which is in turn responsible for only 15% of group revenue. So? So that's 6% of total revenue that's at risk from ozempic style drugs. And you've seen the share price fall 25%. So multiples of that revenue that you know, you would you would assume the only the only justification for that would be a complete annihilation or disappearance of all of that revenue. But the reaction fails to take into account the fact that the renal failure aspect of the Viper business has nothing to do with weight, and tends to impact the aged. Yeah. So, so so we're seeing these overreactions on the downside for companies like CSL. ResMed is another one. The belief is that

5:52

everyone is going to take this drug. And by the way, they can't because they can't afford it. They simply can't afford this. And they have to be on it forever. Because as soon as you come off ozempic, your weight comes back and so it gets more expensive. You have to take more of it. And a large portion of the obese population of the world can't afford these drugs. So it'll still be transformational for the revenues of the inventors, but it won't be so transformational for the revenues of those companies that are being sold off. Yeah, totally. Roger, I heard actually a really good description by a US investor just sort of saying, you know, you might you still go to McDonald's when you're, let's say, on his epic. But instead of having the whole hamburger, you'll only take 1 or 2 bites. But it goes to your point about behavioral changes not taking place necessarily because of the drugs. Let's touch on ResMed, though. We might get the share price just back up again, because ResMed has also been hit on a number of fronts. But this whole thing about the

6:51

Eli Lilly,

6:53

they're doing a sleep apnea test to see whether or not their GLP one will will help. But ResMed has also done a massive piece of research to say, you know, the market is still extremely large for ResMed. If anything, they will work in combination with the GLP one, not, you know, working against them. Well, I actually think that's and that is a really interesting discussion to be having. But let's not forget that there are 100 million obesity sufferers in the United States. They can't all afford their treatment because the annual cost of example is US 10 to $15,000 a year.

7:34

Obesity is a disease with a socioeconomic element, and so a lot of people who are obese simply can't afford ozempic. So it really to me, it doesn't matter whether or not, as Mpic demonstrates, that it's going to be effective for sleep apnea or not. It's still not going to be affordable for a great number of people for whom you know the treatment of the symptoms is is more affordable and therefore something that they're going to continue purchasing. Yeah, absolutely. So is ResMed also one that you considered buying in this latest sell off? Yes it is. What we know though, and I'm just sort of sharing some of my insights, you know, from sort of three decades of doing this CSL is is regarded as as unquestionably high quality and safe. And so it's like more likely that that's the one that investors pile into when they think the overreaction to Ozempic has gone too far. And so that's probably why you see

8:34

CSL up 2% today in ResMed. Not. Yeah, absolutely. Just on a slightly different topic. It looks increasingly like those great quality companies that prove they can operate through the cycle are really proving their worth at the moment. I was just writing about the difference between what Zero's come out with versus James Hardie. I mean, James Hardie is really tackling what is a challenging macro backdrop, and yet they're still managing to put the runs on the board. Do you think this earnings season and going forward? Roger, it really is a case of those quality companies. And I'm not saying Xero is not a quality company, but they're just they've got offshore expansion issues but more now. So than what we've seen in the last two years. It really is a great stock picking market if you can get the right companies. So there's definitely been Danielle. There's definitely been a

9:33

herding into quality defensives. Um, the the issue that investors face now is that many defensives are expensive. So you've got expensive defensives. And I actually think that, for example, the the S&P 600 small cap index, the p e ratio for that index at the moment is 12. Now that's only the. Ratio has been only been lower than 12 on three other occasions one during the 2022 sell off when interest rates were jacked up

10:12

during the Covid sell off, and also during the GFC. So in the last quarter century, there's only been three occasions where we've seen peers for small caps this cheap. So I actually think the real defensive investment is innovative growth companies in the small cap space, both here in Australia and in the US, rather than Defensives, which is where everyone's herded at the moment. Okay. Can you can you throw out a couple of names? Possibly because I would, you know, just a casual observer might say, well, if it's that extreme, Roger, what is what is that telling you? Either the markets possibly got too bearish as we were talking about before, or maybe it's signaling that the US might have a recession. Therefore, you have to be really careful as you then

11:00

go on. Sorry. Yeah. Well the possibility of recession is is ever present at the moment, you know, whether we sidestep it or not. Actually think let me suggest this. I actually think that a recession and we saw a we saw an analyst talk about this last week or earlier this week rather, you know, a recession could, counterintuitively, actually be better for innovative growth stocks simply because it means higher rates hang around for a shorter period of time. So if we have persistent inflation with positive growth, which is what we've got at the moment, then we might see rates stay at these elevated levels for quite some time. But if we get a recession, counter-intuitively, that means it's more likely that rates will be cut and that will be a boost to companies that can still grow at double digit rates. So, counterintuitively, a recession would actually be good for small cap stocks and innovative growth stocks, you know, rather than rather than speculate on the small cap

12:00

stocks that we think are going well, you know, we've just talked about CSL. I really do believe that is a relatively safe place to park money at the moment.

More like this

We value your privacy

We use essential cookies to make the site work. Non-essential cookies help us improve the experience. You can accept or reject non-essential cookies. Privacy policy